AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PANTERA MINERALS LTD

0.013

-0.001-7.14%

Volume:115.45K

Turnover:1.54K

Market Cap:6.16M

PE:-0.30

High:0.014

Open:0.014

Low:0.013

Close:0.014

Loading ...

Overview Company News Filings

Pfizer Unit Biohaven Settles False Claims Case for $60 Million

MT Newswires Live

Pfizer Resolves Do No Harm's Legal Challenge to Fellowship Program

MT Newswires Live

Pfizer Says Metastatic Colorectal Cancer Combination Therapy Shows Significant Survival Benefit

MT Newswires Live

What To Expect in the Markets This Week

Market Chatter: Pfizer Seen Getting Respite From Battle With Activist Investor Starboard

MT Newswires Live

Pfizer to Pay $59.7 Million to Resolve Biohaven's Alleged Kickback Scheme for Nurtec ODT

MT Newswires Live

Pfizer's BRAFTOVI Combination Gets FDA Approval, Improves Outcomes in Colorectal Cancer

MT Newswires Live

Market Chatter: Pfizer Appeals Ruling on $75.2 Million Insider Trading Settlement

MT Newswires Live

Pfizer Reportedly to Sell $3.05 Billion Worth of Haleon Shares

MT Newswires Live

Sector Update: Health Care Stocks Slide Late Afternoon

MT Newswires Live

Sector Update: Health Care Stocks Fall Tuesday Afternoon

MT Newswires Live

Market Chatter: Pfizer CEO Bourla Downplays Dispute With Activist Investor Starboard Value

MT Newswires Live

Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

MT Newswires Live

Pfizer Says Sasanlimab Combination Prolongs Event-Free Survival in Phase 3 Bladder Cancer Trial

MT Newswires Live

Zentalis Pharma Says FDA Grants Fast Track Status on Azenosertib Cancer Drug Candidate

MT Newswires Live

GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, FDA Says

MT Newswires Live

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires Live

Pfizer, Atavistik Bio Team Up to Discover New Precision Allosteric Therapeutics

MT Newswires Live

US Equities Markets End Lower Tuesday In Last Trading Session of 2024

MT Newswires Live

Sector Update: Health Care Stocks Lower in Afternoon Trading

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PFE.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFE.AU\",,,,,undefined,":{"symbol":"PFE.AU","market":"AU","secType":"STK","nameCN":"PANTERA MINERALS LTD","latestPrice":0.013,"timestamp":1749190320000,"preClose":0.014,"halted":0,"volume":115447,"delay":0,"nameEN":"PANTERA MINERALS LTD","floatShares":307273263,"shares":473783688,"eps":-0.043813,"marketStatus":"Market Closed","change":-0.001,"latestTime":"06-06 16:12:00 AEST","open":0.014,"high":0.014,"low":0.013,"amount":1537,"amplitude":0.071429,"askPrice":0.014,"askSize":245673,"bidPrice":0.013,"bidSize":700362,"shortable":3,"etf":0,"ttmEps":-0.043813,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1749513600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.014,"openAndCloseTimeList":[[1749168000000,1749189600000]],"volumeRatio":0.2759394614703392,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFE.AU\",,,,,undefined,":{"symbol":"PFE.AU","floatShares":307273263,"roa":"-48.29%","roe":"-79.97%","lyrEps":-0.043813,"volumeRatio":0.2759394614703392,"shares":473783688,"dividePrice":0,"high":0.014,"amplitude":0.071429,"preClose":0.014,"low":0.013,"week52Low":0.013,"pbRate":"0.47","psRate":"-134.13","week52High":0.049,"institutionHeld":0,"latestPrice":0.013,"committee":0.480626,"eps":-0.043813,"divideRate":0,"volume":115447,"delay":0,"ttmEps":-0.043813,"open":0.014,"prevYearClose":0.018,"prevWeekClose":0.014,"prevMonthClose":0.014,"prevQuarterClose":0.017,"fiveDayClose":0.014,"twentyDayClose":0.014,"sixtyDayClose":0.016},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFE.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508216401","title":"Pfizer Unit Biohaven Settles False Claims Case for $60 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2508216401","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508216401?lang=en_us&edition=fundamental","pubTime":"2025-02-04 02:37","pubTimestamp":1738607855,"startTime":"0","endTime":"0","summary":"Pfizer's  Biohaven agreed to a nearly $60 million nationwide settlement for submitting false claims to Medicaid and other government healthcare programs, California Attorney General Rob Bonta said Monday.The settlement resolves allegations that Biohaven engaged in a kickback scheme from 2020 to 2022, offering cash and gifts to healthcare providers in exchange for Nurtec prescriptions, according to the Bonta.Pfizer will make the payment of $59.7 million plus interest on behalf of Biohaven and it will be shared by the federal government and several states including California, whose share is $413,776, the state's Attorney General added.Neither Pfizer nor Biohaven immediately responded to MT Newswires' requests for comment.Price: 26.26, Change: -0.26, Percent Change: -0.98","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4533","LU1894683348.USD","SG9999002224.SGD","LU1057294990.SGD","LU0225284248.USD","LU1066051498.USD","SG9999013999.USD","LU0289739699.SGD","LU0234572021.USD","SG9999001176.SGD","BK4568","LU0058720904.USD","PFE.AU","LU1894683264.USD","SGXZ57979304.SGD","SG9999011175.SGD","IE0002270589.USD","IE00BLSP4239.USD","LU0225771236.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4534","BK4581","LU0985481810.HKD","IE00B19Z3581.USD","BK4550","BK4585","LU0321505868.SGD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU1883839398.USD","SG9999002232.USD","SG9999001176.USD","LU0122379950.USD","BK4599","BK4007","BK7095","LU0306807586.USD","BK4592","LU0868494617.USD","PFE","BK4588","IE00BLSP4452.SGD","SG9999003800.SGD","LU0170899867.USD","LU0321505439.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2508110801","title":"Pfizer Resolves Do No Harm's Legal Challenge to Fellowship Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2508110801","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508110801?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:48","pubTimestamp":1738586937,"startTime":"0","endTime":"0","summary":"Pfizer  has resolved the legal challenge filed by advocacy group Do No Harm to the company's Breakthrough fellowship program, with a New York district court dismissing the case Friday.According to the court document, Pfizer changed the criteria for the program in February 2023 and has announced that it will no longer accept new applications after the program's fifth and final cohort of fellows.Do No Harm filed the lawsuit in September 2022, claiming that the program was \"racially discriminatory.\"Pfizer did not immediately respond to MT Newswires' request for comment.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0306807586.USD","BK4599","LU0225284248.USD","BK4592","LU1894683264.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU1023059063.AUD","PFE","PFE.AU","BK7095","LU1883839398.USD","SG9999001176.USD","LU0058720904.USD","LU0289739699.SGD","LU0321505868.SGD","SG9999011175.SGD","LU1066051498.USD","SG9999002224.SGD","BK4585","LU0122379950.USD","IE000M9KFDE8.USD","LU0306806265.USD","BK4581","LU0985481810.HKD","LU0456855351.SGD","SG9999002232.USD","SGXZ57979304.SGD","BK4534","IE00B19Z3581.USD","BK4588","SG9999001176.SGD","LU0225771236.USD","IE0002270589.USD","LU0321505439.SGD","LU0170899867.USD","IE00BLSP4239.USD","BK4568","BK4550","SG9999003800.SGD","IE00B19Z3B42.SGD","BK4007","IE00BBT3K403.USD","LU1066053197.SGD","LU1894683348.USD","SG9999013999.USD","BK4533","LU0868494617.USD","LU1057294990.SGD"],"gpt_icon":1},{"id":"2508123931","title":"Pfizer Says Metastatic Colorectal Cancer Combination Therapy Shows Significant Survival Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2508123931","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508123931?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:06","pubTimestamp":1738584382,"startTime":"0","endTime":"0","summary":"Pfizer  said Monday its phase 3 study of Braftovi combination regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients with a type of metastatic colorectal cancer.The company said Braftovi, in combination with cetuximab and mFOLFOX6, also showed a significant improvement in overall survival compared to patients receiving standard chemotherapy, with or without bevacizumab, a key secondary endpoint in the trial.The drugmaker said it plans to share the results with the US Food and Drug Administration to potentially support full approval of the Braftovi combination regimen in patients.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4592","IE0002270589.USD","LU0306806265.USD","LU0225771236.USD","BK4568","IE00BBT3K403.USD","LU0456855351.SGD","BK4599","SG9999002232.USD","SG9999002224.SGD","LU1066051498.USD","LU1883839398.USD","LU1894683348.USD","BK4007","BK4581","LU1023059063.AUD","LU1894683264.USD","BK4533","LU0868494617.USD","LU0122379950.USD","BK4585","LU0234572021.USD","LU0306807586.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","SG9999011175.SGD","IE00B19Z3581.USD","LU0321505868.SGD","BK4550","SG9999013999.USD","LU1066053197.SGD","LU0170899867.USD","SG9999003800.SGD","IE00BLSP4452.SGD","SG9999001176.SGD","SG9999001176.USD","SGXZ57979304.SGD","LU0289739699.SGD","BK4534","BK4588","BK7095","LU0985481810.HKD","LU0225284248.USD","IE00BLSP4239.USD","LU0321505439.SGD","LU1057294990.SGD","LU0058720904.USD","PFE","PFE.AU"],"gpt_icon":1},{"id":"2508630182","title":"What To Expect in the Markets This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2508630182","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508630182?lang=en_us&edition=fundamental","pubTime":"2025-02-02 18:00","pubTimestamp":1738490400,"startTime":"0","endTime":"0","summary":"Earnings from tech, media, and pharmaceutical firms could be in the spotlight this week, with Google parent Alphabet  and Amazon  set to report, along with Disney  and weight-loss drugmakers Novo Nordisk  and Eli Lilly .As the Federal Reserve watches the strength of the labor market, the January employment report is scheduled for Friday, with jobless claims and private sector payrolls also due for release this week. Several Fed officials are set to deliver remarks as well.Senior Loan Officer Opinion Survey on Bank Lending Practices . Atlanta Fed President Raphael Bostic is scheduled to deliver remarks. Palantir , Equity Residential , and Tyson Foods  are scheduled to report earnings. San Francisco Fed President Mary Daly and Atlanta Fed President Raphael Bostic are scheduled to deliver remarks. Chicago Fed President Austan Goolsbee is scheduled to deliver remarks. Novo Nordisk , Walt Disney , Qualcomm , Arm Holdings , Uber Technologies , and MicroStrategy  are scheduled to report earni","market":"us","thumbnail":"https://www.investopedia.com/thmb/uu_OqHrFAaX-LvlHoFvt9c-gsvs=/5000x3333/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2166130918-50c04a338cd4480c94e44de0f875beca.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/uu_OqHrFAaX-LvlHoFvt9c-gsvs=/5000x3333/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2166130918-50c04a338cd4480c94e44de0f875beca.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/what-to-expect-in-the-markets-this-week-8783286","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["GOOGL","AMGN","GOOG","EQR.AU","US12M.BOND","USAW.SI","US3Y.BOND","DIS","HON","AZN","PFE","US30Y.BOND","NVO","BK4576","AMD","PFE.AU","PEP","US7Y.BOND","SPOT","MSTR.AU","US6M.BOND","USJW.SI","AMD.AU","NVO.AU","TSN.AU","LLY","LU1883839398.USD","US5Y.BOND","LU0708994859.HKD","CBOE","ARM.AU","TSN","COP","EQR","PM","US2Y.BOND","AMZN","US10Y.BOND","BK4533","PLTR","MRK","BMY","RACE"],"gpt_icon":1},{"id":"2506889565","title":"Market Chatter: Pfizer Seen Getting Respite From Battle With Activist Investor Starboard","url":"https://stock-news.laohu8.com/highlight/detail?id=2506889565","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506889565?lang=en_us&edition=fundamental","pubTime":"2025-01-28 01:49","pubTimestamp":1738000195,"startTime":"0","endTime":"0","summary":"Pfizer  activist investor Starboard Value did not nominate any directors to the drugmaker's board ahead of its annual meeting in April, Bloomberg reported Monday, citing people familiar with the matter.The development offers temporary relief to Pfizer amid concerns raised by Starboard regarding acquisitions and investments, according to the report.But Starboard, which acquired a roughly $1 billion stake in Pfizer last year, could push for board changes in 2026 if they fail to reach a prior settlement agreement, the report said.Neither Pfizer nor Starboard immediately replied to MT Newswires' requests for comment.Shares of Pfizer were up more than 2% in recent trading.Price: 26.70, Change: +0.61, Percent Change: +2.32","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4550","LU1894683348.USD","LU1894683264.USD","IE0002270589.USD","IE00BLSP4452.SGD","LU1883839398.USD","LU0225771236.USD","LU0122379950.USD","SG9999001176.USD","LU0868494617.USD","LU0985481810.HKD","LU1023059063.AUD","LU0321505439.SGD","BK7095","BK4534","BK4592","BK4568","LU1066051498.USD","LU0306806265.USD","IE000M9KFDE8.USD","SG9999001176.SGD","SG9999011175.SGD","BK4585","PFE.AU","IE00BLSP4239.USD","SG9999002232.USD","LU0234572021.USD","SG9999013999.USD","LU1066053197.SGD","BK4581","BK4588","BK4599","LU0058720904.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU1057294990.SGD","BK4007","LU0306807586.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0456855351.SGD","PFE","BK4533","IE00B19Z3581.USD","IE00BBT3K403.USD","LU0225284248.USD","LU0321505868.SGD","LU0170899867.USD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2506375098","title":"Pfizer to Pay $59.7 Million to Resolve Biohaven's Alleged Kickback Scheme for Nurtec ODT","url":"https://stock-news.laohu8.com/highlight/detail?id=2506375098","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506375098?lang=en_us&edition=fundamental","pubTime":"2025-01-27 20:01","pubTimestamp":1737979278,"startTime":"0","endTime":"0","summary":"Pfizer  agreed to pay about $59.7 million to settle allegations that Biohaven Pharmaceutical Holding, before being acquired by Pfizer, defrauded several US health care programs by paying kickbacks to doctors to drive prescriptions of its Nurtec ODT drug for migraine, the US Department of Justice said Friday.According to the statement, Biohaven allegedly paid \"improper remuneration\" to healthcare professionals from March 1, 2020, through September 30, 2022, to induce them to prescribe Nurtec ODT and subsequently submit false claims to Medicare and other federal healthcare programs.The Justice Department said the settlement also resolves a suit filed by a former Biohaven sales representative. However, it was noted that the settlement only resolved allegations, and no liability was determined.Pfizer and Biohaven Pharmaceutical Holding did not immediately respond to MT Newswires' requests for comments.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4592","LU0225771236.USD","SGXZ57979304.SGD","SG9999001176.USD","LU1894683348.USD","SG9999003800.SGD","SG9999011175.SGD","LU0289739699.SGD","LU0868494617.USD","BK4588","LU0306807586.USD","LU0306806265.USD","SG9999002224.SGD","IE000M9KFDE8.USD","LU0321505439.SGD","IE00BBT3K403.USD","IE00B19Z3B42.SGD","BK4007","LU0985481810.HKD","LU0321505868.SGD","SG9999013999.USD","LU1883839398.USD","IE0002270589.USD","LU0234572021.USD","LU1023059063.AUD","PFE","PFE.AU","ODT","LU0456855351.SGD","BK4581","BK4585","SG9999002232.USD","IE00BLSP4452.SGD","BK4534","BK4599","SG9999001176.SGD","BK4533","LU0058720904.USD","IE00B19Z3581.USD","LU1057294990.SGD","LU1894683264.USD","BK4568","LU1066051498.USD","BK4550","IE00BLSP4239.USD","LU1066053197.SGD","LU0122379950.USD","LU0225284248.USD","BK7095","LU0170899867.USD"],"gpt_icon":1},{"id":"2506373564","title":"Pfizer's BRAFTOVI Combination Gets FDA Approval, Improves Outcomes in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2506373564","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506373564?lang=en_us&edition=fundamental","pubTime":"2025-01-27 19:30","pubTimestamp":1737977431,"startTime":"0","endTime":"0","summary":"Pfizer  said Saturday that its Phase 3 BREAKWATER study showed a 61% objective response rate for the BRAFTOVI combination therapy in patients with BRAF V600E-mutant metastatic colorectal cancer, compared to 40% for standard chemotherapy, based on an independent review.The BRAFTOVI treatment, which includes cetuximab and mFOLFOX6, has been approved by the FDA for newly diagnosed patients with this mutation, the company stated.Patients treated with the BRAFTOVI combination had a median response duration of 13.9 months, compared to 11.1 months for those receiving normal chemotherapy, while early overall survival data showed favorable results for the new treatment, Pfizer added.Pfizer said the safety profile of the BRAFTOVI combination was in line with the known effects of the individual treatments.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999013999.USD","LU0868494617.USD","LU1894683264.USD","SG9999002224.SGD","BK4599","LU0122379950.USD","BK4592","LU0321505439.SGD","BK4007","IE00BBT3K403.USD","SG9999001176.SGD","LU0234572021.USD","SGXZ57979304.SGD","LU1894683348.USD","BK4581","SG9999002232.USD","LU0170899867.USD","BK7095","LU0289739699.SGD","LU1066053197.SGD","BK4550","SG9999011175.SGD","BK4585","LU0985481810.HKD","BK4568","IE00B19Z3B42.SGD","LU0306806265.USD","LU1883839398.USD","BK4533","LU1023059063.AUD","SG9999003800.SGD","LU0306807586.USD","IE00B19Z3581.USD","BK4588","LU1066051498.USD","IE00BLSP4452.SGD","PFE","LU0321505868.SGD","IE00BLSP4239.USD","LU0456855351.SGD","SG9999001176.USD","PFE.AU","LU0225284248.USD","LU1057294990.SGD","BK4534","LU0058720904.USD","IE000M9KFDE8.USD","LU0225771236.USD","IE0002270589.USD"],"gpt_icon":1},{"id":"2503122836","title":"Market Chatter: Pfizer Appeals Ruling on $75.2 Million Insider Trading Settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2503122836","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503122836?lang=en_us&edition=fundamental","pubTime":"2025-01-15 20:00","pubTimestamp":1736942403,"startTime":"0","endTime":"0","summary":"Pfizer  has appealed a federal judge's decision denying the company $75.2 million from a 2013 insider trading settlement involving Steven Cohen's former hedge fund SAC Capital Management, Reuters reported late Tuesday.The funds are from SAC's $602 million settlement with the US Securities and Exchange Commission over trades in drugmakers Wyeth and Elan by Mathew Martoma, a former SAC employee who was later convicted of insider trading, the report said.Pfizer argued it deserved the money because a neurologist who tipped Martoma about a 2008 Alzheimer's drug trial owed a fiduciary duty to Wyeth, which Pfizer acquired in 2009, the report added.The US District Judge Victor Marrero ruled in November that Wyeth was not a victim of Martoma's trading, leaving Pfizer ineligible for the funds, Reuters reported.Pfizer has now filed the case with the 2nd US Circuit Court of Appeals in Manhattan, which could take months, the report said.Pfizer did not immediately respond to MT Newswires' request fo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0306806265.USD","LU0058720904.USD","BK4534","BK4592","BK4599","IE00B19Z3581.USD","SG9999011175.SGD","BK4550","BK7095","SG9999001176.SGD","BK4581","LU0321505439.SGD","LU0234572021.USD","BK4533","LU0321505868.SGD","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0985481810.HKD","IE00BBT3K403.USD","BK4007","BK4568","IE00BLSP4452.SGD","SGXZ57979304.SGD","PFE","LU1883839398.USD","BK4585","LU1057294990.SGD","PFE.AU","SG9999001176.USD","LU0289739699.SGD","SG9999002232.USD","LU0170899867.USD","LU0306807586.USD","BK4588","LU0456855351.SGD","LU0225771236.USD","LU1023059063.AUD","LU0225284248.USD","LU1894683348.USD","LU1066053197.SGD","LU0122379950.USD","LU1066051498.USD","LU0868494617.USD","IE0002270589.USD","IE00BLSP4239.USD","IE000M9KFDE8.USD","SG9999002224.SGD","SG9999013999.USD","LU1894683264.USD"],"gpt_icon":1},{"id":"2503611228","title":"Pfizer Reportedly to Sell $3.05 Billion Worth of Haleon Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2503611228","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503611228?lang=en_us&edition=fundamental","pubTime":"2025-01-15 19:35","pubTimestamp":1736940911,"startTime":"0","endTime":"0","summary":"Pfizer  is seeking to sell more than half of its stake or 2.50 billion British pounds  worth of shares in Haleon , multiple news outlets reported Wednesday, citing bookrunner JPMorgan .The sale of 700 million shares at 3.57 pounds per share would lower Pfizer's stake in the UK consumer healthcare firm, which makes Sensodyne, Panadol, Centrum, and Advil, to 7.3% from 15%, Reuters reported.Pfizer, which will continue to be Haleon's largest shareholder after the sale, said in 2023 it would reduce its stake in a \"slow and methodical\" manner within months, Reuters reported.Pfizer, JPMorgan, and Haleon did not immediately reply to MT Newswires' requests for comment.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0215105999.USD","IE00BJTD4N35.SGD","LU1496350502.SGD","LU2237443549.SGD","IE00B19Z3581.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0203347892.USD","PFE","LU1917777945.USD","IE00BWXC8680.SGD","LU1066053197.SGD","LU2430703178.SGD","BK7095","SG9999001176.SGD","LU0289739699.SGD","LU0211326755.USD","BK4588","LU1894683348.USD","PFE.AU","LU0251132253.USD","BK4516","LU1670627923.USD","SG9999001176.USD","LU1668664300.SGD","LU1914381329.SGD","IE00B1XK9C88.USD","LU1064131342.USD","LU2505996681.GBP","LU2237443978.SGD","LU2023250504.SGD","IE0034235303.USD","LU0267386448.USD","LU2264538146.SGD","SG9999013999.USD","BK4207","BK4568","LU0456855351.SGD","LU1720051017.SGD","LU0211327993.USD","IE0002270589.USD","LU0208291251.USD","IE0034235188.USD","LU2237443622.USD","IE00BLSP4239.USD","HLN","LU2242649171.HKD","LU2552382058.USD","LU1244550577.SGD","LU0417517546.SGD"],"gpt_icon":1},{"id":"2503168182","title":"Sector Update: Health Care Stocks Slide Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2503168182","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503168182?lang=en_us&edition=fundamental","pubTime":"2025-01-15 04:54","pubTimestamp":1736888049,"startTime":"0","endTime":"0","summary":"Health care stocks declined late Tuesday afternoon with the NYSE Health Care Index falling 1.3% and the Health Care Select Sector SPDR Fund  dropping 1.2%.The iShares Biotechnology ETF  shed 1.9%.In regulatory news, UnitedHealth Group's  OptumRx, CVS Health's  Caremark Rx and Cigna's  Express Scripts marked up a number of specialty generic drugs at their affiliated pharmacies by hundreds or thousands of percent, the US Federal Trade Commission said Tuesday.In corporate news, Johnson & Johnson's  shares rose 0.1%. S&P Global Ratings said it placed almost all of the company's ratings on creditwatch with negative implications following its $14.6 billion deal to buy Intra-Cellular Therapies .Firefly Neuroscience  shares surged 73%. The company said its BNA technology platform is able to assess a patient's biological brain age using cognitive data, potentially leading to a \"scalable\" approach to early screening for Alzheimer's patients.Eli Lilly  shares tumbled 6.9% after the company lowere","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","LU1267930573.SGD","SGXZ81514606.USD","LU0985481810.HKD","LU1623119135.USD","LU1496350502.SGD","LU0661504455.SGD","LU2361044949.HKD","LU0861579265.USD","IBB","LU0109394709.USD","LU1035773651.USD","LU2237443978.SGD","LU0211326839.USD","LU2089284900.SGD","CVS.AU","LU0795875169.SGD","AIFF","IE00BJT1NW94.SGD","LU0354030438.USD","LU0077335932.USD","PFE.AU","LU1670628061.USD","JNJ","LU1551013425.SGD","LU0211331839.USD","LU2028103732.USD","SGXZ31699556.SGD","UNH","XLV","LU1261432733.SGD","LLY","LU0058720904.USD","CVS","LU2111349929.HKD","IE0004445239.USD","LU1244550494.USD","LU1935042991.SGD","SG9999002224.SGD","PFE","LU0949170772.SGD","LU2087625088.SGD","LU1548497426.USD","LU0792757196.USD","CI","LU1712237335.SGD","LU0965509283.SGD","IE0002270589.USD","ITCI","GB00BDT5M118.USD"],"gpt_icon":1},{"id":"2503550002","title":"Sector Update: Health Care Stocks Fall Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2503550002","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503550002?lang=en_us&edition=fundamental","pubTime":"2025-01-15 02:59","pubTimestamp":1736881173,"startTime":"0","endTime":"0","summary":"Health care stocks declined Tuesday afternoon with the NYSE Health Care Index falling 1.5% and the Health Care Select Sector SPDR Fund  dropping 1.1%.The iShares Biotechnology ETF  shed 1.1%.In corporate news, Eli Lilly  shares tumbled 6.5% after the company lowered Q4 and full-year revenue expectations amid slower-than-expected growth in its US incretin division.Pfizer  Chief Executive Officer Albert Bourla said the company's dispute with activist investor Starboard Value is over issues \"on the margins\" of its business and is not \"an aggressive situation,\" Bloomberg reported. Pfizer shares fell 1.2%.Illumina  reported preliminary Q4 non-GAAP earnings of $0.91 to $0.93 per diluted share. Analysts polled by FactSet expect $0.91. The shares slumped 4.2%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0820561909.HKD","LU2360106947.USD","SG9999011175.SGD","LU2237443978.SGD","LU0058720904.USD","LU2361044865.SGD","PFE","LU1804176565.USD","XLV","IE00BLSP4452.SGD","LU0689472784.USD","LU0289739699.SGD","IE00B19Z3581.USD","LU0094547139.USD","SG9999002224.SGD","LU2491049909.HKD","LU2089984988.USD","LU1868836591.USD","SGXZ81514606.USD","LU2112291526.USD","LU0823416689.USD","LU1623119135.USD","IE0009355771.USD","LU2468319806.SGD","SG9999013999.USD","LU0868494617.USD","LU1066051498.USD","LU1868837300.USD","BK4534","SG9999014914.USD","LU1868836757.USD","LU1057294990.SGD","LU2237443382.USD","SGXZ51526630.SGD","IBB","IE00B2B36J28.USD","LU1023059063.AUD","LU1093756325.SGD","LLY","LU1366192091.USD","LU2361044949.HKD","LU2211815571.USD","LU0096364046.USD","LU0820561818.USD","BK7095","LU0385154629.USD","ILMN","LU0225771236.USD","PFE.AU","LU1712237335.SGD"],"gpt_icon":1},{"id":"2503456521","title":"Market Chatter: Pfizer CEO Bourla Downplays Dispute With Activist Investor Starboard Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2503456521","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503456521?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:13","pubTimestamp":1736856827,"startTime":"0","endTime":"0","summary":"Pfizer  Chief Executive Albert Bourla said the company's dispute with activist investor Starboard Value is over issues \"on the margins\" of its business and is not \"an aggressive situation,\" Bloomberg reported Tuesday, citing lunchtime remarks with a group of reporters.Bourla said Starboard has not demanded major changes such as cost cuts, board reshuffles, or a corporate breakup, the report cited Bourla as saying.\"I respect Starboard, and I try to be engaged with them,\" Bourla reportedly said. \"If they have good ideas, we will do it.\"Starboard did not immediately reply to MT Newswires' request for comment.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0306806265.USD","LU0058720904.USD","BK4534","BK4592","BK4599","IE00B19Z3581.USD","SG9999011175.SGD","BK4550","BK7095","SG9999001176.SGD","BK4581","LU0321505439.SGD","LU0234572021.USD","BK4533","LU0321505868.SGD","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0985481810.HKD","IE00BBT3K403.USD","BK4007","BK4568","IE00BLSP4452.SGD","SGXZ57979304.SGD","PFE","LU1883839398.USD","BK4585","LU1057294990.SGD","PFE.AU","SG9999001176.USD","LU0289739699.SGD","SG9999002232.USD","LU0170899867.USD","LU0306807586.USD","BK4588","LU0456855351.SGD","LU0225771236.USD","LU1023059063.AUD","LU0225284248.USD","LU1894683348.USD","LU1066053197.SGD","LU0122379950.USD","LU1066051498.USD","LU0868494617.USD","IE0002270589.USD","IE00BLSP4239.USD","IE000M9KFDE8.USD","SG9999002224.SGD","SG9999013999.USD","LU1894683264.USD"],"gpt_icon":1},{"id":"2502609819","title":"Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure","url":"https://stock-news.laohu8.com/highlight/detail?id=2502609819","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502609819?lang=en_us&edition=fundamental","pubTime":"2025-01-11 03:37","pubTimestamp":1736537823,"startTime":"0","endTime":"0","summary":"Arvinas  shares fell 5.7% in recent Friday trading after the company outlined plans for a data update on a breast cancer drug in collaboration with Pfizer .Topline data from the monotherapy phase 3 VERITAC-2 trial of vepdegestrant is anticipated in Q1 for patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer, Arvinas said Friday in a statement.Two new phase 3 combination trials for first- and second-line treatment are scheduled, pending regulatory feedback, Arvinas said,\"With the prioritization of the vepdegestrant plus atirmociclib combination for the first-line setting, the VERITAC-3 trial evaluating vepdegestrant plus palbociclib in the first line will not proceed beyond the study lead-in,\" the company said.The company plans to file an investigational new drug application for the PROTAC KRAS G12D degrader to treat various types of cancer.Arvinas said Chief Commercial Officer John Northcott is leaving for personal reas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2506951792.HKD","LU1894683264.USD","IE00BLSP4452.SGD","SG9999001176.SGD","BK7095","LU0823414551.USD","LU0868494617.USD","LU2357125470.USD","BK4585","ARVN","IE00BBT3K403.USD","BK4007","LU0122379950.USD","IE0002270589.USD","LU2249611893.SGD","LU0321505439.SGD","LU0985481810.HKD","BK4533","LU2294711713.HKD","SG9999013999.USD","SG9999011175.SGD","LU0170899867.USD","LU1066051498.USD","BK4009","SG9999001176.USD","LU0289739699.SGD","BK4588","BK4550","LU0225284248.USD","IE00BLSP4239.USD","LU0058720904.USD","LU0306806265.USD","LU1066053197.SGD","SGXZ57979304.SGD","IE000M9KFDE8.USD","BK4568","BK4581","LU0306807586.USD","LU0321505868.SGD","LU1883839398.USD","LU1023059063.AUD","IE00B19Z3581.USD","LU0225771236.USD","BK4534","BK4592","PFE.AU","LU1894683348.USD","PFE","CCO","LU1057294990.SGD"],"gpt_icon":1},{"id":"2502885794","title":"Pfizer Says Sasanlimab Combination Prolongs Event-Free Survival in Phase 3 Bladder Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2502885794","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502885794?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:25","pubTimestamp":1736511915,"startTime":"0","endTime":"0","summary":"Pfizer  said Friday that its pivotal phase 3 trial evaluating sasanlimab in combination with Bacillus Calmette-Guerin, or BCG, as treatment for non-muscle invasive bladder cancer achieved its primary endpoint of event-free survival.The study showed that the combination therapy provided a \"clinically meaningful and statistically significant improvement\" compared with BCG alone, according to Pfizer.Prolonged event-free survival provided by the investigational treatment may delay or reduce the need for more aggressive treatment options, said Neal Shore, lead investigator for the trial.The safety profile of sasanlimab in combination with BCG \"was generally consistent\" with the known profiles of BCG and PD-1 inhibitors, Pfizer added.The company said sasanlimab is also being investigated in combination with its antibody drug conjugate portfolio in advanced solid tumors.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0306807586.USD","BK4599","LU0225284248.USD","BK4592","LU1894683264.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU1023059063.AUD","PFE","PFE.AU","BK7095","LU1883839398.USD","SG9999001176.USD","LU0058720904.USD","LU0289739699.SGD","LU0321505868.SGD","SG9999011175.SGD","LU1066051498.USD","SG9999002224.SGD","BK4585","LU0122379950.USD","IE000M9KFDE8.USD","LU0306806265.USD","BK4581","LU0985481810.HKD","LU0456855351.SGD","SG9999002232.USD","SGXZ57979304.SGD","BK4534","IE00B19Z3581.USD","BK4588","SG9999001176.SGD","LU0225771236.USD","IE0002270589.USD","LU0321505439.SGD","LU0170899867.USD","IE00BLSP4239.USD","BK4568","BK4550","SG9999003800.SGD","IE00B19Z3B42.SGD","BK4007","IE00BBT3K403.USD","LU1066053197.SGD","LU1894683348.USD","SG9999013999.USD","BK4533","LU0868494617.USD","LU1057294990.SGD"],"gpt_icon":1},{"id":"2502403200","title":"Zentalis Pharma Says FDA Grants Fast Track Status on Azenosertib Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2502403200","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502403200?lang=en_us&edition=fundamental","pubTime":"2025-01-10 01:40","pubTimestamp":1736444417,"startTime":"0","endTime":"0","summary":"Zentalis Pharmaceuticals  said Thursday the US Food and Drug Administration granted fast track designation to the company's azenosertib drug candidate to treat several forms of platinum-resistant gynecological cancers in patients.Fast track designation by the US Food and Drug Administration is intended to support and accelerate development of medicines and therapies showing a strong potential to treat serious medical conditions often lacking effective treatments at this time, the company said.The FDA temporarily placed a partial hold on clinical testing of azenosertib as a monotherapy for ovarian, fallopian tube or primary peritoneal cancers in June 2024 following the death of two trial participants due to suspected blood-related infections. The agency lifted its hold on Sept. 16.Zentalis also said Thursday it will present top-line data from those studies as well as another trial of azenosertib in combination with Pfizer's  encorafenib and Eli Lilly's  cetuximab chemotherapies in patie","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999003800.SGD","LU2602419157.SGD","IE00B2B36J28.USD","IE00BK4W5M84.HKD","LU0321505868.SGD","LU0306806265.USD","SG9999014898.SGD","LU2023250504.SGD","BK4533","BK4592","LU0006306889.USD","SG9999001176.SGD","LU0672654240.SGD","LU0289739699.SGD","LU0471298694.HKD","PFE.AU","SG9999014880.SGD","LU0114720955.EUR","LU2491049909.HKD","LU0985481810.HKD","LU1093756168.USD","LU1868836591.USD","LU2237438978.USD","LU0106261372.USD","BK4516","LU1868837300.USD","IE00BJT1NW94.SGD","FAST","IE00B19Z3581.USD","LU0385154629.USD","SG9999013999.USD","SG9999014906.USD","SG9999018865.SGD","PFE","LLY","SGXZ57979304.SGD","LU0640476718.USD","SG9999018857.SGD","BK4588","LU1057294990.SGD","LU2063271972.USD","LU1917777945.USD","LU1974910355.USD","LU0234572021.USD","LU2237443978.SGD","IE00BJJMRZ35.SGD","IE00B5TLWC47.USD","LU0820561909.HKD","LU0256863902.USD","ZNTL"],"gpt_icon":1},{"id":"2501277194","title":"GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, FDA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2501277194","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501277194?lang=en_us&edition=fundamental","pubTime":"2025-01-08 23:48","pubTimestamp":1736351313,"startTime":"0","endTime":"0","summary":"GSK  and Pfizer's  respiratory syncytial virus vaccines will carry  warnings of increased risk of Guillain-Barre Syndrome, the US Food and Drug Administration said Tuesday on its website.Results from a post-marketing observational study suggested an increased risk of Guillain-Barre Syndrome  during the 42 days after vaccination with Pfizer's Abrysvo and GSK's Arexvy, the FDA said.GBS is a rare disorder in which the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis.The FDA said it has \"determined that the overall body of evidence suggests increased risks of GBS with Abrysvo and Arexvy, but that available evidence is insufficient to establish a causal relationship.\"\"FDA has required and approved safety labeling changes to the Prescribing Information for Abrysvo and Arexvy,\" the regulator said.\"FDA has further determined that the benefits of vaccination with Abrysvo and Arexvy continue to outweigh their risks,\" it added.GSK and Pfizer didn't immedia","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1023059063.AUD","LU0234572021.USD","BK4581","GSK","LU1829250122.USD","LU1894683264.USD","BK4534","LU1883839398.USD","BK4588","LU0306807586.USD","BK4532","IE00B19Z3581.USD","LU1894683348.USD","BK4007","SGXZ57979304.SGD","LU0225771236.USD","LU0058720904.USD","LU1057294990.SGD","GSK.UK","BK7095","SG9999002224.SGD","LU0306806265.USD","LU0289739699.SGD","LU0321505868.SGD","LU0985481810.HKD","LU1066051498.USD","LU1066053197.SGD","SG9999001176.SGD","BK4568","LU0868494617.USD","BK4592","IE000M9KFDE8.USD","LU0170899867.USD","LU0225284248.USD","IE0002270589.USD","PFE.AU","LU0321505439.SGD","SG9999002232.USD","LU0122379950.USD","BK4550","IE00B19Z3B42.SGD","SG9999013999.USD","SG9999011175.SGD","BK4585","IE00BLSP4452.SGD","BK4599","LU0456855351.SGD","PFE","SG9999003800.SGD","SG9999001176.USD"],"gpt_icon":1},{"id":"2500904326","title":"Sector Update: Health Care Stocks Softer Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2500904326","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500904326?lang=en_us&edition=fundamental","pubTime":"2025-01-03 04:57","pubTimestamp":1735851467,"startTime":"0","endTime":"0","summary":"Health care stocks were declining late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  both fractionally lower.The iShares Biotechnology ETF  rose 0.4%.In corporate news, Pfizer  is collaborating with Atavistik Bio to accelerate the discovery of new precision allosteric therapeutics, Atavistik said. Pfizer shares added 0.5%.BioNexus Gene Lab  shares soared 45%. The company said that it was granted temporary exception until May 1 to regain compliance with Nasdaq's minimum bid price rule.NRX Pharmaceuticals  shares surged 35%. The company's Hope Therapeutics unit plans to acquire the Kadima Neuropsychiatry Institute.Neumora Therapeutics  shares plunged past 81% after a phase 3 trial of navacaprant to treat major depressive disorder failed to meet the primary endpoint.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0002270589.USD","LU0234572021.USD","BK4534","LU0306806265.USD","BK4568","BK4592","LU0289739699.SGD","LU0985481810.HKD","LU1057294990.SGD","NRXP","IE00BLSP4239.USD","SG9999002224.SGD","SG9999002232.USD","PFE.AU","SGXZ57979304.SGD","LU1023059063.AUD","IE00BBT3K403.USD","LU0321505439.SGD","IE000M9KFDE8.USD","IBB","SG9999013999.USD","LU0058720904.USD","BK4104","IE00B19Z3581.USD","XLV","LU1066053197.SGD","SG9999003800.SGD","PFE","LU0321505868.SGD","BK4581","LU0225284248.USD","NMRA","SG9999001176.SGD","BK4588","LU1883839398.USD","BK4007","LU0868494617.USD","BK4599","IE00B19Z3B42.SGD","SG9999001176.USD","BGLC","BK4585","LU1894683348.USD","LU0456855351.SGD","LU0170899867.USD","SG9999011175.SGD","BK4550","LU0225771236.USD","LU0122379950.USD","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2500908783","title":"Pfizer, Atavistik Bio Team Up to Discover New Precision Allosteric Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2500908783","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500908783?lang=en_us&edition=fundamental","pubTime":"2025-01-03 02:48","pubTimestamp":1735843720,"startTime":"0","endTime":"0","summary":"Pfizer  is collaborating with Atavistik Bio to accelerate the discovery of new precision allosteric therapeutics, Atavistik said Thursday.Financial terms of the partnership were not disclosed.Under the research partnership, the companies will use Atavistik's AMPS platform to identify allosteric binders against two undisclosed targets picked by Pfizer, according to Atavistik.The collaboration grants Pfizer the option to license the programs at the end of the research period, Atavistik added.Price: 26.61, Change: +0.08, Percent Change: +0.30","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0868494617.USD","LU0985481810.HKD","IE00BLSP4452.SGD","LU0306806265.USD","SG9999003800.SGD","LU1861217088.USD","TISI","LU0170899867.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","BK4166","LU0306807586.USD","SG9999001176.SGD","IE0002270589.USD","LU1023059063.AUD","LU0058720904.USD","BK4534","IE000M9KFDE8.USD","SG9999011175.SGD","PFE.AU","BK4007","LU1791807156.HKD","LU1668664300.SGD","LU1066051498.USD","LU1883839398.USD","LU0122379950.USD","LU0234572021.USD","LENZ","BK4550","LU1066053197.SGD","BK4585","BK4533","LU2360107671.USD","BK4568","LU1861220207.SGD","IE00BLSP4239.USD","LU1894683264.USD","BK4599","PFE","IE00B19Z3581.USD","BK4139","IE00BBT3K403.USD","LU0225284248.USD","LU1057294990.SGD","BK7095","LU0321505868.SGD","BK4581","LU0225771236.USD","BK4120","DFS"],"gpt_icon":0},{"id":"2500640301","title":"US Equities Markets End Lower Tuesday In Last Trading Session of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2500640301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500640301?lang=en_us&edition=fundamental","pubTime":"2025-01-01 05:02","pubTimestamp":1735678924,"startTime":"0","endTime":"0","summary":"US benchmark equity indexes ended lower on the last trading day of the year while posting double-digit gains in 2024.Markets will be closed Wednesday for New Year's Day.* US home prices increased to r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0345774391.USD","IE00BBT3K403.USD","SPGI","GB00BDT5M118.USD",".IXIC","NQmain","TSYW.SI","BK4548","DJX","DOG","TQQQ","MNQmain","LU2271345857.HKD","LU2764263203.CNY","BK4592","DXD","UDOW","X","SGMO","USJW.SI","PSQ","LU2095319765.USD","USAW.SI","LU2264538146.SGD","SG9999013999.USD","SQQQ",".SPX","SGXZ57979304.SGD","LU2764263039.SGD","LU0122379950.USD","LU1989764664.SGD","BK4006","BK4585","NVIW.SI","SG9999018865.SGD","BK4534","BK4520","BK4581","PFE.AU",".DJI","IE00B19Z3581.USD","QID","LU1989764748.USD","PFE","QLD","SDOW","LU2089283258.USD","SG9999001176.SGD","DDM"],"gpt_icon":1},{"id":"2500460746","title":"Sector Update: Health Care Stocks Lower in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2500460746","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500460746?lang=en_us&edition=fundamental","pubTime":"2025-01-01 02:51","pubTimestamp":1735671116,"startTime":"0","endTime":"0","summary":"Health care stocks fell Tuesday afternoon with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund  easing 0.1%.The iShares Biotechnology ETF  rose 0.1%.In corporate news, Verastem  shares jumped 46% after the US Food and Drug Administration accepted and granted priority review to a new drug application for its ovarian cancer drug and set an action date of June 30.Kazia Therapeutics  shares fell 37% after the company said it was considering options for its drug candidate paxalisib after the US Food and Drug Administration discouraged an accelerated approval process for the potential glioblastoma treatment.Sangamo Therapeutics  shares sank 55% after it said its partner Pfizer  decided not to proceed with further development of a new gene therapy to treat hemophilia A, a bleeding disorder.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PFE","BK4139","LU0058720904.USD","SG9999013999.USD","LU1066051498.USD","IE0002270589.USD","BK4592","LU0122379950.USD","LU1883839398.USD","IE00BLSP4452.SGD","BK7095","VSTM","BK4568","PFE.AU","KZIA","LU0225284248.USD","BK4585","SG9999001176.USD","LU0868494617.USD","SG9999002224.SGD","BK4556","IBB","IE00B19Z3B42.SGD","LU0170899867.USD","LU0985481810.HKD","SGXZ57979304.SGD","IE000M9KFDE8.USD","LU0321505439.SGD","SG9999003800.SGD","LU0234572021.USD","SG9999002232.USD","BK4550","LU0306807586.USD","LU1057294990.SGD","XLV","LU0321505868.SGD","BK4534","LU1066053197.SGD","SG9999011175.SGD","BK4533","BK4007","BK4588","IE00B19Z3581.USD","IE00BLSP4239.USD","LU0225771236.USD","SG9999001176.SGD","IE00BBT3K403.USD","SGMO","LU1894683264.USD","BK4599"],"gpt_icon":1}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":103,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFE.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFE.AU\",market:\"AU\",,,undefined,":[]}}